Saniya Exports & Imports

Saniya Exports & Imports, established in 2015, is a privately held Indian company specializing in the export of Ayurvedic and herbal pharmaceutical formulations. The company is headquartered at X/208/E, White House, Manjummal P.O., near Muttar Bridge, Ernakulam, Kerala, India. The proprietor of the company is Mr. Dalton Joseph. Saniya Exports & Imports has demonstrated a consistent growth trajectory, with a total export value of $190,000 USD and 473 shipments recorded between 2022 and 2026. The company exports five finished pharmaceutical formulations across a single therapeutic category, Ayurvedic & Herbal Products, with a portfolio concentration of 100% in this segment.

Specific details regarding the manufacturing facilities of Saniya Exports & Imports are not publicly disclosed. The company exports finished pharmaceutical formulations, indicating that manufacturing is likely conducted in compliance with Good Manufacturing Practices (GMP) standards. However, without explicit information, a comprehensive assessment of their manufacturing capabilities cannot be provided.

The company is led by Mr. Dalton Joseph, who serves as the Proprietor. Specific information regarding other key executives, such as a Chief Executive Officer (CEO) or Chief Financial Officer (CFO), is not publicly available. The absence of detailed leadership information limits the ability to assess the company's executive structure and strategic direction.

Saniya Exports & Imports primarily exports Ayurvedic and herbal pharmaceutical formulations, which are subject to regulatory approvals in various markets. While the company has engaged in trade with the United Arab Emirates (UAE), specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The lack of publicly accessible regulatory information restricts a comprehensive analysis of the company's presence in these regulated markets.

Saniya Exports & Imports has engaged in trade with the United Arab Emirates (UAE), indicating a presence in the Middle East market. However, specific information regarding the company's penetration into African, Latin American, or Southeast Asian markets is not publicly available. The absence of data on WHO prequalification or other certifications that enable access to these regions limits the ability to assess the company's reach in emerging markets.

Saniya Exports & Imports has demonstrated a focused geographic strategy, primarily exporting to the United Arab Emirates (UAE). This concentration suggests a strategic emphasis on the Middle East market. The lack of diversification into other regions may expose the company to risks associated with over-reliance on a single market. A more diversified geographic strategy could mitigate potential risks and open avenues for growth in other regions.

Specific information regarding Saniya Exports & Imports' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history is not publicly available. The absence of such data limits the ability to assess the company's compliance with FDA regulations and its standing in the U.S. market.

There is no publicly available information regarding Saniya Exports & Imports' WHO prequalification status, EU GMP certificates, or EDQM status. The lack of such certifications may impact the company's ability to access certain international markets that require adherence to these standards.

Specific details regarding Saniya Exports & Imports' CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly disclosed. The absence of this information limits the ability to assess the company's compliance with Indian regulatory requirements.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with Saniya Exports & Imports. The lack of such data suggests that the company may not have faced significant regulatory actions in recent years.

Saniya Exports & Imports operates in the Ayurvedic and herbal pharmaceutical formulations segment, exporting products such as Taila, Arishta, Kwatha, Ghrita, and Asava. While specific market share data is not available, the company's focus on this niche market positions it among competitors specializing in Ayurvedic and herbal products. The absence of publicly available data on competitors' market shares and product offerings limits a detailed competitive analysis.

Saniya Exports & Imports' key differentiator lies in its specialization in Ayurvedic and herbal pharmaceutical formulations. The company's portfolio concentration of 100% in this segment indicates a deep focus and expertise in traditional medicine products. However, the lack of publicly available information on product quality certifications and regulatory approvals may impact the company's competitive advantage in certain markets.

Saniya Exports & Imports appears to be strategically positioned in the Ayurvedic and herbal pharmaceutical formulations market, with a concentrated product portfolio. The company's focus on this niche segment suggests a specialization strategy. However, the lack of diversification in product offerings and geographic markets may limit growth opportunities and expose the company to risks associated with market concentration.

Saniya Exports & Imports has demonstrated a consistent export volume, with 473 shipments recorded between 2022 and 2026. The company's primary trading partner is Sabha General Trading Co LLC in the United Arab Emirates, indicating a stable business relationship. However, the absence of publicly available information on the company's financial stability, supply chain practices, and adherence to international quality standards limits a comprehensive assessment of its reliability as a supplier.

Importers should verify the following certifications when considering Saniya Exports & Imports as a supplier:

• FDA Facility Registration: To ensure compliance with U.S. regulations. Verification can be done through the FDA's official website.

• WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices. Verification can be done through the WHO's official website.

• EU GMP Certification: To ensure compliance with European Union Good Manufacturing Practices. Verification can be done through the European Medicines Agency's official website.

• ISO Certification: To confirm adherence to international quality management standards. Verification can be done through the International Organization for Standardization's official website.

When conducting due diligence on Saniya Exports & Imports, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Assess Financial Stability: Review financial statements and credit reports to evaluate the company's financial health.

• Evaluate Product Quality: Request product samples and review quality control processes to ensure product standards.

• Review Supply Chain Practices: Assess the company's supply chain for reliability and ethical practices.

• Check References: Contact previous clients and partners to gather feedback on the company's performance and reliability.

Be cautious of red flags such as a lack of transparency, inconsistent product quality, or negative feedback from previous partners. Conducting thorough due diligence is essential to mitigate risks and ensure a successful business relationship.